Literature DB >> 23893239

Dual role of sphingosine kinase-1 in promoting the differentiation of dermal fibroblasts and the dissemination of melanoma cells.

V Albinet1, M-L Bats1, A Huwiler2, P Rochaix3, C Chevreau4, B Ségui1, T Levade5, N Andrieu-Abadie1.   

Abstract

Despite progress in the understanding of the biology and genetics of melanoma, no effective treatment against this cancer is available. The adjacent microenvironment has an important role in melanoma progression. Defining the molecular signals that control the bidirectional dialog between malignant cells and the surrounding stroma is crucial for efficient targeted therapy. Our study aimed at defining the role of sphingosine-1-phosphate (S1P) in melanoma-stroma interactions. Transcriptomic analysis of human melanoma cell lines showed increased expression of sphingosine kinase-1 (SPHK1), the enzyme that produces S1P, as compared with normal melanocytes. Such an increase was also observed by immunohistochemistry in melanoma specimens as compared with nevi, and occurred downstream of ERK activation because of BRAF or NRAS mutations. Importantly, migration of melanoma cells was not affected by changes in SPHK1 activity in tumor cells, but was stimulated by comparable modifications of S1P-metabolizing enzymes in cocultured dermal fibroblasts. Reciprocally, incubation of fibroblasts with the conditioned medium from SPHK1-expressing melanoma cells resulted in their differentiation to myofibroblasts, increased production of matrix metalloproteinases and enhanced SPHK1 expression and activity. In vivo tumorigenesis experiments showed that the lack of S1P in the microenvironment prevented the development of orthotopically injected melanoma cells. Finally, local tumor growth and dissemination were enhanced more efficiently by coinjection of wild-type skin fibroblasts than by fibroblasts from Sphk1(-/-) mice. This report is the first to document that SPHK1/S1P modulates the communication between melanoma cells and dermal fibroblasts. Altogether, our findings highlight SPHK1 as a potential therapeutic target in melanoma progression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23893239     DOI: 10.1038/onc.2013.303

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

1.  An integrative study to identify novel scaffolds for sphingosine kinase 1 inhibitors.

Authors:  Marcela Vettorazzi; Emilio Angelina; Santiago Lima; Tomas Gonec; Jan Otevrel; Pavlina Marvanova; Tereza Padrtova; Petr Mokry; Pavel Bobal; Lina M Acosta; Alirio Palma; Justo Cobo; Janette Bobalova; Jozef Csollei; Ivan Malik; Sergio Alvarez; Sarah Spiegel; Josef Jampilek; Ricardo D Enriz
Journal:  Eur J Med Chem       Date:  2017-08-10       Impact factor: 6.514

2.  A novel sphingosine kinase 1 inhibitor (SKI-5C) induces cell death of Wilms' tumor cells in vitro and in vivo.

Authors:  Zhi-Heng Li; Yan-Fang Tao; Li-Xiao Xu; He Zhao; Xiao-Lu Li; Fang Fang; Yi Wu; Jun Lu; Yan-Hong Li; Wei-Wei Du; Jun-Li Ren; Yi-Ping Li; Yun-Yun Xu; Xing Feng; Jian Wang; Wei-Qi He; Jian Pan
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

3.  Reduction of COX-2 through modulating miR-124/SPHK1 axis contributes to the antimetastatic effect of alpinumisoflavone in melanoma.

Authors:  Ming Gao; Yuan Chang; Xiuyong Wang; Chao Ban; Fan Zhang
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

Review 4.  Sphingolipids and Lymphomas: A Double-Edged Sword.

Authors:  Alfredo Pherez-Farah; Rosa Del Carmen López-Sánchez; Luis Mario Villela-Martínez; Rocío Ortiz-López; Brady E Beltrán; José Ascención Hernández-Hernández
Journal:  Cancers (Basel)       Date:  2022-04-19       Impact factor: 6.575

5.  Host sphingosine kinase 1 worsens pancreatic cancer peritoneal carcinomatosis.

Authors:  Hiroaki Aoki; Masayo Aoki; Eriko Katsuta; Rajesh Ramanathan; Michael O Idowu; Sarah Spiegel; Kazuaki Takabe
Journal:  J Surg Res       Date:  2016-07-09       Impact factor: 2.192

Review 6.  Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.

Authors:  Zhengyi Wang; Xiaoying Wu
Journal:  Cancer Med       Date:  2020-09-02       Impact factor: 4.452

7.  Activating Sphingosine-1-phospahte signaling in endothelial cells increases myosin light chain phosphorylation to decrease endothelial permeability thereby inhibiting cancer metastasis.

Authors:  Yu-Chi Chen; Saketh S Dinavahi; Qilong Feng; Raghavendra Gowda; Srinivasa Ramisetti; Xinghai Xia; Kyle B LaPenna; Venkat R Chirasani; Sung Hyun Cho; Susan L Hafenstein; Madhu Babu Battu; Arthur Berg; Arun K Sharma; Tom Kirchhausen; Nikolay V Dokholyan; Shantu Amin; Pingnian He; Gavin P Robertson
Journal:  Cancer Lett       Date:  2021-02-16       Impact factor: 9.756

8.  Similarities in Gene Expression Profiles during In Vitro Aging of Primary Human Embryonic Lung and Foreskin Fibroblasts.

Authors:  Shiva Marthandan; Steffen Priebe; Mario Baumgart; Marco Groth; Alessandro Cellerino; Reinhard Guthke; Peter Hemmerich; Stephan Diekmann
Journal:  Biomed Res Int       Date:  2015-08-03       Impact factor: 3.411

9.  A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties.

Authors:  Melissa R Pitman; Jason A Powell; Carl Coolen; Paul A B Moretti; Julia R Zebol; Duyen H Pham; John W Finnie; Anthony S Don; Lisa M Ebert; Claudine S Bonder; Briony L Gliddon; Stuart M Pitson
Journal:  Oncotarget       Date:  2015-03-30

Review 10.  Re-configuration of sphingolipid metabolism by oncogenic transformation.

Authors:  Anthony S Don; Xin Y Lim; Timothy A Couttas
Journal:  Biomolecules       Date:  2014-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.